6NQ Stock Overview
A pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Synthaverse S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.96 |
| 52 Week High | zł1.28 |
| 52 Week Low | zł0.63 |
| Beta | 1.23 |
| 11 Month Change | -8.10% |
| 3 Month Change | -11.63% |
| 1 Year Change | -2.23% |
| 33 Year Change | -52.79% |
| 5 Year Change | n/a |
| Change since IPO | -78.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6NQ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.5% | 2.6% | 4.5% |
| 1Y | -2.2% | -16.4% | 13.5% |
Return vs Industry: 6NQ exceeded the German Biotechs industry which returned -16.4% over the past year.
Return vs Market: 6NQ underperformed the German Market which returned 13.5% over the past year.
Price Volatility
| 6NQ volatility | |
|---|---|
| 6NQ Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6NQ's share price has been volatile over the past 3 months.
Volatility Over Time: 6NQ's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 239 | Mieczyslaw Starkowicz | www.synthaverse.pl |
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company’s prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma.
Synthaverse S.A. Fundamentals Summary
| 6NQ fundamental statistics | |
|---|---|
| Market cap | €73.23m |
| Earnings (TTM) | €577.82k |
| Revenue (TTM) | €13.40m |
126.7x
P/E Ratio5.5x
P/S RatioIs 6NQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6NQ income statement (TTM) | |
|---|---|
| Revenue | zł57.35m |
| Cost of Revenue | zł22.61m |
| Gross Profit | zł34.74m |
| Other Expenses | zł32.27m |
| Earnings | zł2.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 20, 2024
| Earnings per share (EPS) | 0.035 |
| Gross Margin | 60.57% |
| Net Profit Margin | 4.31% |
| Debt/Equity Ratio | 69.4% |
How did 6NQ perform over the long term?
See historical performance and comparison